ES2107528T3 - Ensayos de la actividad de la amilina. - Google Patents

Ensayos de la actividad de la amilina.

Info

Publication number
ES2107528T3
ES2107528T3 ES92904180T ES92904180T ES2107528T3 ES 2107528 T3 ES2107528 T3 ES 2107528T3 ES 92904180 T ES92904180 T ES 92904180T ES 92904180 T ES92904180 T ES 92904180T ES 2107528 T3 ES2107528 T3 ES 2107528T3
Authority
ES
Spain
Prior art keywords
amyline
open
tests
activity
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92904180T
Other languages
English (en)
Inventor
Andrew Young
Garth James Smith Cooper
Timothy J Rink
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylin Pharmaceuticals LLC
Original Assignee
Amylin Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/640,478 external-priority patent/US5234906A/en
Application filed by Amylin Pharmaceuticals LLC filed Critical Amylin Pharmaceuticals LLC
Application granted granted Critical
Publication of ES2107528T3 publication Critical patent/ES2107528T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE PRESENTAN METODOS PARA SU USO EN LA IDENTIFICACION O EN EL ENSAYO DE COMPUESTOS QUE PUEDAN INHIBIR O SIMULAR LA CAPACIDAD DE LA AMILINA DE PROVOCAR HIPERLACTEMIA Y / O HIPERGLUCEMIA EN MODELOS BIOLOGICOS VIVOS. TAMBIEN SE PRESENTAN METODOS PARA SU USO EN LA EVALUACION DE LA POTENCIA DE LOS COMPUESTOS CONOCIDOS O SOSPECHOSOS DE ESTIMULAR CUALQUIERA O AMBAS DE ESTAS ACCIONES DE LA AMILINA. LA FIGURA MUESTRA LA RESPUESTA DE LA GLUCOSA DEL PLASMA DE RATAS INOCULADAS CON SOMATOSTATINA MAS AMILINA (CIRCULO ABIERTO), CON UN PEPTIDO DE CONTROL (CUADRADO ABIERTO), O CON PENTOLAMINA (TRIANGULO ABIERTO).
ES92904180T 1991-01-10 1992-01-10 Ensayos de la actividad de la amilina. Expired - Lifetime ES2107528T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/640,478 US5234906A (en) 1991-01-10 1991-01-10 Hyperglycemic compositions
US66652791A 1991-03-08 1991-03-08

Publications (1)

Publication Number Publication Date
ES2107528T3 true ES2107528T3 (es) 1997-12-01

Family

ID=27093565

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92904180T Expired - Lifetime ES2107528T3 (es) 1991-01-10 1992-01-10 Ensayos de la actividad de la amilina.

Country Status (10)

Country Link
US (1) US6048514A (es)
EP (1) EP0525149B1 (es)
JP (1) JP2818296B2 (es)
AT (1) ATE155689T1 (es)
CA (1) CA2077265A1 (es)
DE (1) DE69221040T2 (es)
DK (1) DK0525149T3 (es)
ES (1) ES2107528T3 (es)
GR (1) GR3024812T3 (es)
WO (1) WO1992011863A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
NZ253449A (en) * 1992-05-15 1994-12-22 Amylin Pharmaceuticals Inc Monoclonal antibody binding to the c-terminal end of human amylin and kits and assays employing it
AU6249594A (en) * 1993-02-12 1994-08-29 Amylin Pharmaceuticals, Inc. Mcf-7 binding site assays
US6936584B1 (en) 1998-02-13 2005-08-30 Amylin Pharmaceuticals, Inc. Mixed amylin activity compounds
US20040038861A1 (en) * 2001-11-26 2004-02-26 Cooper Garth J. S. Methods and compositions for normalizing lipid levels in mammalian tissues
US20040142393A1 (en) * 2002-08-01 2004-07-22 Cooper Garth James Smith Methods of use of compounds with preptin function
US7339347B2 (en) * 2003-08-11 2008-03-04 Reserve Power Cell, Llc Apparatus and method for reliably supplying electrical energy to an electrical system
EP1719447A1 (de) * 2005-05-07 2006-11-08 F. Hoffmann-La Roche AG Verfahren und Vorrichtung zur Bestimmung der Glucose-Konzentration in Gewebflüssigkeit
CN101808615B (zh) * 2007-08-24 2013-05-15 巴斯夫欧洲公司 包含苯并三唑和部花青的混合物
JP6358942B2 (ja) * 2014-12-05 2018-07-18 沢井製薬株式会社 エンドトキシンの測定用試薬及びエンドトキシンの測定方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8316032D0 (en) * 1983-06-11 1983-07-13 Tanabe Seiyaku Co Benzothiazepine derivatives
US5266561A (en) * 1988-01-11 1993-11-30 Amylin Pharmaceuticals, Inc. Treatment of type 2 diabetes mellitus
US5280014A (en) * 1988-01-11 1994-01-18 Amylin Pharmaceuticals, Inc. Treatment of obesity and essential hypertension and related disorders
US5260275A (en) * 1990-08-14 1993-11-09 Amylin Pharmaceuticals, Inc. Hypoglycemics
US5321008A (en) * 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
US5234906A (en) * 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
US5376638A (en) * 1992-09-01 1994-12-27 Amylin Pharmaceuticals, Inc. Methods for treating renin-related disorders with amylin antagonists

Also Published As

Publication number Publication date
US6048514A (en) 2000-04-11
JPH05505625A (ja) 1993-08-19
DE69221040D1 (de) 1997-09-04
GR3024812T3 (en) 1998-01-30
CA2077265A1 (en) 1992-07-11
EP0525149A4 (en) 1993-08-25
ATE155689T1 (de) 1997-08-15
DE69221040T2 (de) 1997-11-13
DK0525149T3 (da) 1997-12-01
EP0525149B1 (en) 1997-07-23
EP0525149A1 (en) 1993-02-03
JP2818296B2 (ja) 1998-10-30
WO1992011863A1 (en) 1992-07-23

Similar Documents

Publication Publication Date Title
ES2075050T3 (es) Peptidos que tienen actividad cooperadora de celulas t.
ES547040A0 (es) Perfeccionamientos en los aparatos portatiles de vigilancia cardiaca y metodos correspondientes
IT8867010A0 (it) Protesi valvolare cardiaca
ES2080739T3 (es) Nitro-compuestos insecticidamente activos.
BR7902093A (pt) Aperfeicoamento em protese de valvula cardiaca
NL7700578A (nl) Gesubstitueerde n-fenyl-n'-benzoylurea, een werkwijze voor de bereiding daarvan en de toe- passing als insekticide.
IT8812558A0 (it) Poltrona per abbronzatura
BR8004905A (pt) Protese de valvula cardiaca
ES2043607T3 (es) Agentes fibrinoliticos modificados.
ES2150989T3 (es) Nuevos derivados de quinoxalinadiona, su preparacion y empleo en medicamentos.
BR9006835A (pt) Agentes de controle biologico aperfeicoado de insetos,e metodos de uso
ES2107528T3 (es) Ensayos de la actividad de la amilina.
ES2151607T3 (es) Factor 12 de crecimiento y de diferenciacion.
DE69131842D1 (de) Piperidinderivate und ihre Verwendung als antiarrhythmische Wirkstoffe
DE3889302D1 (de) 9-(Acylamino)tetrahydroacridinderivate und wahrnehmungssteigernde Mittel davon als aktiver Wirkstoff.
DE58902290D1 (de) Sauerstoffabsorptionsmittel und verwendung desselben.
DE59002510D1 (de) Mittel gegen Keratinschädlinge.
DE69616944D1 (de) Verwendung von des-aspartat-angiotensin i als wirkstoff gegen herzhypertrophie
FI77046B (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara peptider.
ES2052850T3 (es) Un procedimiento para preparar un compuesto de hidrazona.
ES2181787T3 (es) Derivados de la 3h-2,3-benzodiazepina sustituidos en posicion 3, y su su utilizacion como medicamentos
ES2017601A4 (es) Pirazolas sustituidas y su uso como herbicidas
FI844645A0 (fi) 1,7-difenyl-3-metylaza-7-cyan-8 -metyl-nonan foer anvaendning vid bekaempning av sjukdomar.
ES2072869T3 (es) Uso de derivados de la 1,4-dihidropiridina en el tratamiento del alcoholismo.
BE874430A (fr) 2,3-dihydroimidazo (1,2,c) pyrimidines substituees et leur utilisation therapeutique

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 525149

Country of ref document: ES